Meditor Group Ltd decreased its stake in Exelixis Inc (EXEL) by 5.35% based on its latest 2017Q4 regulatory filing with …
Exelixis, Inc. (EXEL - Free Report) delivered a stellar first-quarter 2018, wherein both earnings and revenues beat estimates on strong performance of Cabometyx. Following the announcement of the results, shares of Exelixis gained 5.97% in …
Exelixis, Inc. EXEL was a big mover last session, as the company saw its shares rise nearly 8% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This reverses the recent trend …
EXEL) today announced that data from clinical trials of cabozantinib will be the subject of 15 presentations at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting in Chicago, June 1-5, 2018. Poster presentations will …
*Constant currency basis: constant currency figures are calculated by translating the current year figures at prior year …
Exelixis, Inc. is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company's cabozantinib product is an …
And then, in April 2009, one month after the stock market hit its lowest point during the financial crisis, I started tracking …
On March 7, Merck (MRK) announced that it had entered a collaboration with Eisai for the co-development and co-commercialization of the latter’s oral protein tyrosine kinase inhibitor, Lenvima, as a monotherapy and in combination …